US Pharma giant Pfizer announced that the vaccine against the Covid-19 disease, which is being developed by US pharmaceutical giant Pfizer and German biotech firm BioNTech, is 90m percent effective in preventing infections in the ongoing Phase-III trials.

Pfizer’s chairperson and CEO Albert Bourla said, “The first set of results from our Phase-III Covid-19 vaccine trial provides the initial evidence of our vaccine’s capability to prevent Covid-19. We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis,”

Protection in patients was achieved 7 days after the second of two doses, and 28 days after the first, according to preliminary findings. The findings are based on an interim analysis conducted after 94 participants contracted the illness. The trial will go on until 164 cases have occurred. The preliminary results lay strong footings for the companies to seek an emergency-use authorization from regulators if further research shows the shot is also safe.

Wine sales fall due to Corona, these states suffered losses

US becomes the first nation to cross 10 million COVID-19 cases

India reports 45 thousand new cases in last 24 hours, Corona case cross 85 million mark